Baxter Intl Inc Stock Price, News & Analysis

Baxter International will participate in the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, with CFO Jay Saccaro presenting at 10:40 a.m. ET. The presentation will be accessible via a live webcast at www.baxter.com, and available for replay until September 13, 2021. Baxter is a leader in medical products, providing critical care, nutrition, and renal products globally for over 85 years.

Baxter International and Moderna have entered an agreement for Baxter's BioPharma Solutions to manufacture and supply packaging for approximately 60-90 million doses of the Moderna COVID-19 Vaccine in 2021. The manufacturing will occur in Bloomington, Indiana, utilizing Baxter's 20 years of experience in vaccine production. This partnership aims to enhance Moderna's manufacturing capacity in the U.S., allowing for the expedited rollout of the vaccine to meet public health needs.

Baxter International (NYSE:BAX) has appointed Dr. David S. Wilkes to its board of directors, enhancing its leadership with his extensive medical and biotech experience. Dr. Wilkes, dean of the University of Virginia School of Medicine, will serve on Baxter’s Quality, Compliance and Technology Committee. Albert P.L. Stroucken is named lead independent director, succeeding Thomas T. Stallkamp, who remains on the board. The changes reflect Baxter's commitment to diversify its board while maintaining experienced oversight. The board now consists of 13 members.

Baxter International (NYSE:BAX) has declared a quarterly cash dividend of $0.245 per share, payable on April 1, 2021, to shareholders on record as of February 26, 2021. This sets an annual indicative dividend rate at $0.98 per share. Baxter, with over 85 years of experience, focuses on critical care, nutrition, and surgical products, impacting millions globally. The company’s forward-looking statements suggest that future dividend payouts may vary based on several risk factors.

Baxter International reported fourth-quarter sales of $3.2 billion, a 5% year-over-year increase, despite a flat U.S. market. International sales rose 8%, driven by Acute Therapies demand during COVID-19. Fourth-quarter net income was $168 million or $0.33 per share, influenced by special items totaling $244 million. For 2020, sales reached $11.7 billion, up 3%, with net income of $1.1 billion. The company expects 2021 sales growth of 7-8% and adjusted earnings per share of $3.35 to $3.43. Baxter remains committed to shareholder value and innovation amidst ongoing challenges.

Baxter International (NYSE:BAX) will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021, at 10:40 a.m. Eastern Time. Jay Saccaro, the company’s CFO, is scheduled to speak. A live webcast of the presentation will be available on www.baxter.com and can be replayed until May 25, 2021. Baxter has a legacy of over 85 years in transforming healthcare through innovations in critical care, nutrition, renal, and surgical products, serving patients in over 100 countries.

Baxter International has announced an agreement with Novavax to provide sterile manufacturing services for the COVID-19 vaccine candidate NVX-CoV2373. This partnership aims to support commercial-scale manufacturing for distribution in the UK and Europe. The facility in Halle/Westfalen, Germany, will ensure compliance with cGMP standards. Currently in phase 3 trials, the vaccine has not yet received authorization. Novavax's vaccine utilizes recombinant nanoparticle technology, aiming to provide a safe and effective solution amid the ongoing pandemic.

Baxter International Inc. (NYSE:BAX) announced a conference call to discuss its fourth-quarter 2020 financial results scheduled for February 4, 2021, at 7:30 a.m. Central Time. Interested participants can pre-register using the provided link or access the webcast via Baxter’s website. The call will be recorded and is copyrighted material.

Baxter has been a trusted provider of healthcare products for over 85 years, offering critical care, nutrition, and renal products in over 100 countries.

Baxter International (NYSE:BAX) will present at the 39th Annual J.P. Morgan Healthcare Conference via webcast. CEO José Almeida is scheduled to speak on January 11, 2021, at 9:10 a.m. ET. Investors can access the live webcast and slides at www.baxter.com, with replays available until February 11, 2021. Baxter has been a vital player in healthcare for over 85 years, providing critical care, nutrition, and surgical products across more than 100 countries.